Document:

Exhibit 10.10

                              MASTER CLINICAL TRIAL
                                       AND
                       FULL SCALE MANUFACTURING AGREEMENT

         This Master Clinical Trial Drug and Full Scale Manufacturing Agreement
("Agreement") is entered into this 5th day of October 2004 ("Effective Date") by
and between Samaritan Pharmaceuticals, Inc., a Nevada corporation with offices
at 101 Convention Center Drive, Suite 310, Las Vegas, Nevada 89109 ("Samaritan")
and Pharmaplaz, Ltd. ("Pharmaplaz"), an Irish Corporation with offices at
Daneswell Business Park, Monksland, Athlone, County Roscommon, Ireland
(individually, a "Party" and collectively, the "Parties").

                                 R E C I T A L S

         WHEREAS Pharmaplaz is engaged in the business of pharmaceutical active
ingredient outsourcing, offering combinations of proprietary and process
chemistry technologies, contract process research, development services,
clinical trial-scale contract manufacturing and full scale manufacturing;

         WHEREAS, Samaritan may from time to time desire to participate in
clinical research designed to determine the safety and/or efficacy of a drug or
device in human subjects thereby advancing medical care;

         WHEREAS, Samaritan may from time to time desire to participate in full
scale manufacturing designed to determine the safety and/or efficacy of a drug
or device in human subjects thereby advancing medical care;

         WHEREAS, Samaritan believes, based upon the representations of
Pharmaplaz, that Pharmaplaz has the facilities and the personnel with the
requisite skills, experience and knowledge in conducting clinical trials and as
a contract manufacturer of pharmaceuticals to undertake such research and
development as a coordinating center for its Studies and to subsequently
manufacture Samaritan Product;

         WHEREAS, Samaritan and Pharmaplaz desire to enter into this Agreement
to provide the terms and conditions upon which Samaritan may engage Pharmaplaz
to participate in Studies as may be mutually agreed between Samaritan and
Pharmaplaz;

         WHEREAS, Samaritan and Pharmaplaz desire to enter into this Agreement
to engage in Studies that may both further develop a new drug or device and
benefit patients as described in the risks and benefits provisions of any
informed consent associated with a Study;

         WHEREAS, the Studies contemplated by this Agreement shall be of mutual
interest and benefit to Samaritan and Pharmaplaz, and shall further the
instructional and research objectives of Samaritan's collaborators in a manner
consistent with the collaborators status as a non-for profit research and
healthcare entity where applicable;

<PAGE>

         WHEREAS, the Studies contemplated by this Agreement may lead to Full
Scale Manufacturing Contract ("FSMC"), and Samaritan and Pharmaplaz may desire
to enter into this Agreement to provide terms and conditions upon which
Samaritan may engage Pharmaplaz to participate in full scale manufacturing as
may be mutually agreed between Samaritan and Pharmaplaz.

                                   DEFINITIONS

         "cGMP" shall mean the good manufacturing practices promulgated by the
FDA from time to time and the corollary regulations promulgated by the EMEA.

         "Commercial Purposes" shall mean the sale, lease, license, or other
transfer of the Product or Modifications to a for-profit organization.
Commercial Purposes shall also include uses of the Product or Modifications by
any organization, including Pharmaplaz, to perform contract research, to screen
compound libraries, to produce or manufacture products for general sale, or to
conduct research activities that result in any sale, lease, license, or transfer
of the Product or Modifications to a for-profit organization.

         "Components" shall mean all those items necessary to manufacture the
Product.

         "Development Committee" shall mean a group of representatives appointed
by the parties responsible for implementing a FSMC as set forth in Section 1.7
of this Agreement.

         "EMEA" shall mean the European Medical Ethics Association or any other
European Union (E.U.) body with the authority to promulgate and enforce
regulations related to the development and marketing of drugs and devices as
amended from time to time. Together with the EMEA, these shall be known as
Regulatory Authorities.

         "FDA" shall mean the United States Food and Drug Administration which
administers the federal Food, Drug and Cosmetic Act, and its ensuing regulations
as amended from time to time. Together with the EMEA shall collectively be known
as Regulatory Authorities.

         "Major Change" shall mean a change as determined by Samaritan that
would be likely to have a significant impact on the critical quality attributes
of production and process control designed to assure that the drug products have
the identity, strength, quality, and purity they purport or are represented to
possess.

         "Minor Change" shall mean a change as determined by Samaritan unlikely
to have a detectable impact on critical attributes of production and process
control designed to assure that the drug products have the identity, strength,
quality, and purity they purport or are represented to possess.

         "Moderate Change" shall mean a change as determined by Samaritan that
could have a significant impact on quality attributes of production and process
control designed to assure that the drug products have the identity, strength,
quality, and purity they purport or are represented to possess.

<PAGE>

         "Modifications" shall mean Substances created by Pharmaplaz which
contain / incorporate the Product.

         "NDA" shall mean a New Drug Application as defined by the applicable
Regulatory Authorities.

         "Nonprofit Organizations(s)" shall mean a university or other
institution of higher education or an organization of the type described in
section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. 501(c)) and
exempt from taxation under section 501(a) of the Internal Revenue Code (26
U.S.C. 501(a)) or any nonprofit scientific or educational organization qualified
under a state nonprofit organization statute. As used herein, the term also
includes government agencies.

         "Original Product" shall mean the description of the material being
transferred as specified in each Addendum.

         "Participating Institution(s)" shall mean those clinical sites
conducting the Studies.

         "Pharmaplaz Principal Investigator" shall mean an employee by or under
contract to Pharmaplaz who bears responsibility for the intellectual leadership
of a project. The principal investigator accepts overall responsibility for
directing the research, the financial oversight of the contract's funding, as
well as compliance with relevant Samaritan's policies, terms and conditions of
contract.

         "Product" shall include: (a) Modifications; or (b) Improvements; or (c)
new Inventions; or (d) Unmodified Derivatives.

         "Progeny" shall mean the unmodified descendant from the Product, such
as virus from virus, cell from cell, or organism from organism.

         "Regulatory Authorities" shall mean the FDA, the EMEA and other
countries' regulatory bodies and/or their successor agencies whose
responsibility it is to review and approve a drug and/or device for market and
subsequently regulate certain marketing activities.

         "Samaritan Principal Investigator" shall mean an employee by or under
contract to Samaritan who bears responsibility for the intellectual leadership
of a project. The principal investigator accepts overall responsibility for
directing the research, the financial oversight of the contract's funding, as
well as compliance with relevant Samaritan's policies, terms and conditions of
contract.

          "Specifications" shall mean the exact manufacturing instructions for
the product which Pharmaplaz will manufacture for Samaritan.

         "Study" or "Studies" shall mean a clinical trial designed to determine
the safety, efficacy and dosage of a drug or device in human subjects.

<PAGE>

         "Unmodified Derivatives" shall mean substances created by Pharmaplaz,
which constitute an unmodified functional subunit or product expressed by the
Original Product. Some examples include: subclones of unmodified cell lines,
purified or fractionated subsets of the original material, proteins expressed by
DNA/RNA supplied by Samaritan, or monoclonal antibodies secreted by a hybridoma
cell line.

         NOW, THEREFORE, in consideration of the foregoing facts and the mutual
covenants set forth herein, the Parties hereto agree as follows:

1. Scope of Work.

1.1      Clinical Trial Work. The Study and the clinical trial protocol for the
         research to be conducted by Pharmaplaz under this Agreement designed by
         Samaritan which describes the Study protocol, shall be attached hereto
         as an Addendum and incorporated as part of this Agreement. This shall
         be done for each Study. Each Addendum shall be in a form substantially
         like that attached hereto as Appendix A and shall include the Scope of
         Work including, but is not limited to, the detailed information
         concerning the given Study, including a description of the specific
         research to be conducted, project milestones, target completion dates,
         a detailed budget, and a Payment Schedule related to the Scope of Work
         and Budget. Except as otherwise stated therein, each Addendum shall be
         subject to the terms and conditions of this Agreement. Each Addendum
         shall be signed by an authorized representative of each Party prior to
         initiation of any work under that Addendum. Nothing in this Agreement
         shall obligate either Party to enter into any Addendum.

1.2      Principal Investigator. The Studies to be conducted by Pharmaplaz
         hereunder shall each be under the direction of a Principal Investigator
         who will be named in the applicable Addendum and who shall be a
         full-time employee of Pharmaplaz or under contract to Pharmaplaz.
         Samaritan, upon its written request shall be provided a copy of such
         contract of the Principal Investigators' terms of employment.

1.3      Participating Investigators and Institutions. The Principal
         Investigator for each Addendum shall coordinate the Study, and the work
         being performed at the Participating Institutions. Pharmaplaz shall
         enter into an agreement with each Participating Institution containing
         terms consistent with those in this Agreement and the applicable
         Addendum. Pharmaplaz shall ensure that the data generated by the
         Participating Institutions shall be kept confidential, coordinated,
         analyzed and reported in an efficient and effective manner and in a
         format fully usable by Samaritan. Pharmaplaz shall be responsible for
         enrolling Study patients, obtaining fully executed informed consents
         from those Study patients, interfacing with the Institutional Review
         Board ("IRB") for each Participating Institution when requested by
         Samaritan to do so and reporting all adverse events which may occur
         during the Studies to Samaritan in such a manner and form to enable
         Samaritan to make the required reports to the appropriate Regulatory
         Authorities. The informed consent must be approved by Samaritan before
         use in a Study.

1.4      Supply and Use of the Product. Pharmaplaz shall provide Samaritan
         and/or the Participating Institution with sufficient drug, device,
         placebo, or comparator drug or device to be investigated in a Study and
         shall supply all other materials to perform each Study on a timely
         basis. The Product shall be shipped "FOB point of Destination."
         Pharmaplaz also agrees that the Products shall be used only for
         Samaritan Studies. Any Product remaining at the end of a Study shall be
         returned or disposed of in accordance with Samaritan's instructions.

<PAGE>

1.5      Warranty, Manufacturing Standards and Quality Assistance. Pharmaplaz
         represents and warrants that it has the requisite knowledge and
         expertise in the cGMPs and conducts all its manufacturing practices in
         accordance with the cGMPs or corollary regulations. Pharmaplaz
         covenants that at the time of manufacture of the Product it will be in
         full compliance with the cGMPs and will be prepared for a successful
         inspection of its manufacturing facility.

          (a)  Product Warranty.  Pharmaplaz warrants that the Product delivered
               to Samaritan under this Agreement shall, at the time of delivery,
               (i) conform to the Specifications, (ii) conform to all additional
               product   Specifications   mutually   agreed   upon  for  Product
               attributes and possible cross contaminants  resultant from common
               equipment and  facilities  utilized in the  manufacturing  of the
               Product and other products manufactured by Pharmaplaz,  and (iii)
               Pharmaplaz's  production  of the Product  shall be  conducted  in
               accordance  with  current  cGMPs as listed in 21 CFR 211 or other
               applicable   regulations.   Pharmaplaz   further   warrants   and
               guarantees  that,  as of the date of each  delivery  hereunder to
               Samaritan, and until its date of expiration, the Product, whether
               for intended sale in the United States or elsewhere, shall comply
               with the provisions of the applicable Regulatory  Authorities and
               such  Product  shall  not,  when  delivered,  be  adulterated  or
               misbranded  within  the  meaning  of  those  regulations  of  the
               Regulatory  Authorities.   To  the  extent  that  the  provisions
               promulgated  by  the  Regulatory  Authorities  of a  country  are
               different  from those of the United States,  Pharmaplaz  shall be
               responsible  for  identifying  and  bearing  the cost  for  those
               differences.  Samaritan  shall promptly amend the  Specifications
               necessary to comply with the applicable  Regulatory  Authorities'
               provisions  in such  country.  Pharmaplaz  agrees  that more than
               twelve  (12)  months of the total  approved  shelf  life for each
               dosage  form of the  Product  upon  delivery  of such  Product to
               Samaritan,  except with respect to batches of Product as to which
               investigative  testing or  re-testing  is required in  accordance
               with  Section   1.5(b)  below.   Products  shall  be  labeled  in
               accordance  with  Samaritan's  instructions  and  the  applicable
               regulatory  scheme as amended from time to time by the Regulatory
               Authorities.

          (b)  Product  Inspection.  Pharmaplaz will test and inspect product in
               accordance  21 Code of Federal  Regulations  (CFR)  Parts 211 for
               compliance with  specifications.  If within  forty-five (45) days
               after  receipt of Product by Samaritan or its designee  Samaritan
               or its designee notifies  Pharmaplaz in writing that such lots do
               not meet the  Specifications  as determined by Samaritan's or its
               designee's  testing and  inspection  of the  Product,  Pharmaplaz
               shall replace the Product  (subject to Section 1.5(c) below),  at
               Pharmaplaz's  expense  (such  expense  to  include  the  cost  of
               Components  and  Products)  within  forty-five  (45) days of such
               notice.  Pharmaplaz  shall pay  shipping  charges to deliver such
               replacement   Product   to   Samaritan   or   its   designee.   A

<PAGE>

               non-conforming Product shall, upon mutual agreement by Pharmaplaz
               and  Samaritan,  either (1) be  returned to  Pharmaplaz  within a
               reasonable  period of time or (2) be  destroyed  by  Samaritan at
               Pharmaplaz's  expense.  Pharmaplaz shall bear all  costs/expenses
               associated with a failed batch, including,  but not limited to, a
               failed  Study for  clinical  batches and product  recalls for all
               Products which are on the market.

          (c)  Disputes  with  Respect  to  Rejection.  If  Pharmaplaz  disputes
               Samaritan's  right to reject all or part of any  shipment  of the
               Product as set forth in Section 1.5(b)  hereof,  and such dispute
               is not resolved by mutual  agreement  between the parties  within
               sixty (60) days of Samaritan's notice of rejection,  such dispute
               shall be  resolved  by an  independent  testing  organization  or
               consultant  of   recognized   repute  within  the  U.S.  or  E.U.
               pharmaceutical  industry with experience and expertise in dealing
               with the applicable Regulatory Authorities,  mutually agreed upon
               by  the  parties,   the   appointment   of  which  shall  not  be
               unreasonably   withheld   or   delayed  by  either   Party.   The
               determination  of such testing entity with respect to Samaritan's
               rejection of the shipment or portion  thereof  shall be final and
               binding  upon the  parties,  but only as to the reasons  given by
               Samaritan in rejecting the shipment or portion  thereof and shall
               have no effect on any matter for which said entity did not render
               a determination.  The fees and expenses of the third party making
               the  determination  shall be paid by the Party  against which the
               determination is made.

          (d)  Master Formula.  The composition of the Product will be as stated
               in the approved Product NDA or the applicable regulatory approval
               for such Product as submitted to the Regulatory Authorities. This
               Master  Formula  shall not be disclosed by  Pharmaplaz  to anyone
               outside its company  without  the express  knowledge  and written
               consent of Samaritan.  Pharmaplaz shall be solely responsible for
               the  activities  of its  employees in keeping the Master  Formula
               confidential.

          (e)  Manufacturing  and  Packaging  Instruction  and  Procedures.  The
               Product  will be  manufactured  and  packaged  as  stated  in the
               applicable  approved  Product  NDA or the  applicable  regulatory
               approval for Product.  Product master manufacturing and packaging
               procedures  to be set forth in the Product  master batch  records
               shall be mutually approved by the parties.

          (f)  Change  Control.  Pharmaplaz  shall  implement  a change  control
               system in accordance  with 21 Code of Federal  Regulations  (CFR)
               Parts  210,  211,  314 and  Scale-Up  and  Post  Approval  Change
               (SUPAC).  Pharmaplaz  will notify  Samaritan  or its  designee in
               writing of any proposed  "Moderate  Change" or "Major  Change" to
               Products or  Components  of the Product,  process  Specifications
               and/or controls, as well as third party contractors, equipment or
               facilities   or   analytical   methodology   utilized   for   the
               manufacturing,  packaging,  and/or  analytical  evaluation of the
               Product.  Any "Moderate  Change" or "Major Change" must be agreed
               upon and approved in writing by Samaritan prior to implementation
               or   submission   to   Regulatory   Authorities   for   approval.
               Documentation   supporting   the  change   will  be  provided  by
               Pharmaplaz  in a form  appropriate  for  submission to Regulatory
               Authorities.  Submissions  of, and changes to, the package insert
               and  label  shall  be  the  responsibility  of  Samaritan  or its
               designee.

<PAGE>

          (g)  Batch Records.  Records which include the information relating to
               the manufacturing,  packaging, and quality operation for each lot
               of the Product  shall be prepared  by  Pharmaplaz  at the time at
               which such operations  occur. The records shall include,  but are
               not  limited  to,  the  following  documentation:  manufacturing,
               Products and Components  charge-in  records;  mixing and fillings
               records;   packaging  component   charge-in  records;   packaging
               records;  container and component traceability records; equipment
               usage records;  in-process and final laboratory  testing results;
               in-process and final product physical inspection  results;  yield
               reconciliation  for bulk and  finished  product;  label  samples;
               labeling  control records;  as well as documentation  listing any
               deviations and/or excursions from approved  procedure (as well as
               the Pharmaplaz  investigation  and corrective  actions)  incurred
               during the  processing  and  packaging  of the lot.  The original
               documents  for  each  lot may be  reviewed  by  Samaritan  at its
               request when auditing the  Pharmaplaz  site of manufacture of the
               Product.  These and all other  related  records  shall be kept in
               accordance  with FDA and E.U.  regulations.  Any changes in batch
               records  relating  to the  manufacturing,  packaging  and quality
               operations  must be agreed upon in writing by Samaritan  prior to
               implementation.  Documentation  supporting  the  change  will  be
               provided  by  Pharmaplaz   for   submission  to  the   Regulatory
               Authorities.   Submission  of  documentation  to  the  Regulatory
               Authorities  shall  be the  responsibility  of  Samaritan  or its
               designee.

          (h)  Batch  Document to be Included  With Each  Shipment of Product to
               Samaritan.   The  minimum  batch  documentation  required  to  be
               included  with each lot of Product  shipped to  Samaritan  or its
               designee  is  a  packaging   bill  of  material   and  copies  of
               certificate  of  analysis  for  each  lot.  The   certificate  of
               analysis,   signed  by  the  responsible   quality   official  of
               Pharmaplaz,  must include the numerical  results,  if applicable,
               for each test  (chemical,  microbiological  and  bacteriological)
               performed  to  assure  results  are in  compliance  with  Product
               Specifications,  as  well as a  statement  that  subject  lot was
               produced in  accordance to the  applicable  NDA and in compliance
               with  all  applicable  cGMP   requirements.   It  is  solely  the
               obligation  of  Pharmaplaz  to ensure that the cGMPs are complied
               with at all times  with  respect to the  Product  and at the site
               where the Product is manufactured.

          (i)  Chemical  and  Packaging   Component   Inspection   and  Release.
               Pharmaplaz  shall  test,   inspect,   and  release  Products  and
               Components  used in the  manufacture  of the  Product.  Samaritan
               shall supply  approved  masters for labels,  package  inserts and
               labeling to  Pharmaplaz  to be utilized for the Product  supplied
               hereunder.  Pharmaplaz  shall  inspect  and  release  all labels,
               package  inserts,  and  labeling  utilized  for the  Product  for
               conformance  with such approved  masters.  Pharmaplaz shall test,
               inspect and release all other packaging Components for compliance
               with Specifications.

<PAGE>

          (j)  Retention  Sample.  Pharmaplaz  is  responsible  for  storing and
               maintaining  retention  samples of finished Product from each lot
               to meet regulatory  requirements at Pharmaplaz' cost.  Pharmaplaz
               is responsible for storing and maintaining  retention  samples of
               each lot of Product utilized in the manufacture of the Product in
               accordance with all Regulatory Authority requirements, including,
               but not limited to, cGMPs.

          (k)  Product  Complaints.  Pharmaplaz or its  designated  distributors
               shall  correspond  with  complainants  on all product  complaints
               associated  with the  Product  and  shall  file any Drug  Adverse
               Reaction  Experience  Reports  associated  with  the  Product  as
               required  under the  applicable  regulations  of the  appropriate
               Regulatory  Authorities.  Complaints received associated with the
               Product  which may require an NDA Field Alert Report as specified
               under  21 CFR  214.81  shall  be  handled  by  Pharmaplaz  or its
               designated  distributors.  Copies  of any Drug  Adverse  Reaction
               Experience  Reports  and  NDA  Field  Alert  Reports  or  foreign
               equivalents   shall  be  promptly   forwarded   to  Samaritan  by
               Pharmaplaz.  Samaritan or its designee shall assist Pharmaplaz in
               investigating  Product  complaints  by analyzing  the Product and
               Components to determine the cause,  if any, of an alleged Product
               manufacturing defect or failure.  Samaritan or its designee shall
               also assist  Pharmaplaz in the  investigation of any adverse drug
               events when such adverse  events are believed to be  attributable
               to the  Product.  If  Samaritan  has  licensed  the  Product to a
               third-party,  then Samaritan  shall be responsible  for notifying
               its  licensor  under  these  circumstances  and  may  act for the
               licensor  depending  on the  terms of that  licensing  agreement.
               Pharmaplaz  shall  diligently work to provide a written report of
               its  determination  within  fourteen  (14) days from receipt of a
               written request and samples of the involved  Product.  Pharmaplaz
               shall be responsible to ensure that Samaritan receives samples of
               the  Product to be  investigated.  In the event  that  Pharmaplaz
               determines  that any reasonable  additional  physical,  chemical,
               biological,  or other evaluation  should be conducted in relation
               to an adverse drug event or Product  complaint,  Pharmaplaz shall
               so advise  Samaritan.  Pharmaplaz  shall  conduct  the  necessary
               evaluations  and  advise  Samaritan  of the  results.  The  costs
               incurred for  performance  under this  paragraph  1.5(k) shall be
               borne by Pharmaplaz unless  additional  evaluations are requested
               by Samaritan or its  designee and are not  otherwise  required by
               regulation  or not  otherwise  carried out by  Pharmaplaz  in the
               usual course of its investigation  under its applicable  standard
               operating procedures (SOPs) for complaints will be at the expense
               of Samaritan.

          (l)  Process  Validation.  Pharmaplaz  shall  validate all  processes,
               equipment,  utilities  facilities  and computers  utilized in the
               manufacture  packaging,  storage,  testing  and  release  of  the
               Product  for  regulatory   submissions  and  commercial  sale  in
               conformance with all current Regulatory  Authority guidelines and
               regulations. Pharmaplaz shall be responsible for and shall ensure
               that all validated systems are maintained according to Regulatory
               Authority    guidelines   and   that   all   required    periodic
               revalidation's  are  performed  according  to  those  guidelines.
               Samaritan  shall  reserve  the right to review  and  approve  all
               process,  utility,   equipment  and  computer  validation  master
               validation  plans  and/or the  corresponding  protocols  prior to
               execution  of such  validation.  Samaritan  reserves the right to
               review the results of all related validation studies.

<PAGE>

1.6      cGMP Checklist of Responsibilities between Samaritan and Pharmaplaz.

<TABLE>
<CAPTION>

                                                                                                      Contract
                                                                                    Contract Giver    Acceptor
        RESPONSIBILITIES                                                             (Samaritan)    (Pharmaplaz)
        ----------------                                                            --------------  ------------
<S>                                                                                    <C>              <C>
   1    cGMP REQUIREMENTS

  1.1   Manufacture in accordance current U.S. Good Manufacturing Practices as
        listed in 21 CFR 211and the Code of Federal Regulation, as amended from
        time to time, as well as all applicable E.U. regulations related to
        manufacturing                                                                                     X

  1.2   Supply all information necessary for manufacture of the product by the
        contract acceptor                                                                  X

  1.3   Maintain a valid Manufacturing License covering manufacture of the product                        X

  1.4   Manufacture product in strict adherence to the approved procedures                                X

  1.5   Permits audits of all relevant premises, procedures and documentation by
        the contract giver, and permit inspection by the Regulatory Authorities.                          X

  1.6   Not to subcontract any of the manufacturing activities to a third party
        without prior written agreement                                                                   X

  1.7   Make no changes to the product specification or validated manufacturing
        parameters without Samaritan prior written agreement.                                             X

  1.8   Approve all Manufacturing Instructions (Production Operating Instructions)                        X

  1.9   Document any deviation from defined procedures, including approval by
        Production and Quality management                                                                 X

  1.10  Control the quality of all activities and excipients according to
        specification by the application of approved analytical methods                                   X

<PAGE>

  1.11  Batch release by an authorized Qualified Person                                                   X

  1.12  Maintain originals of all batch records for a minimum of one (1) year after
        the expiry date of the product and supply all copies of such records to the
        contract giver upon request.
                                                                       X
                                                                                                       Contract
                                                                                    Contract Giver     Acceptor
        RESPONSIBILITIES                                                              (Samaritan      (Pharmaplaz
        ----------------                                                            --------------  ------------
  2.0   PRODUCTION AND TESTING OF BULK CAPSULES
  2.1   Master Formula per unit of Product                                                 X
  2.2   Product specification                                                              X

  2.3   Batch identification system for bulk manufacture                                                  X

  2.4   Purchase of active substances (including certificates of analysis)                                X

  2.5   Storage of active substances                                                                      X

  2.6   Sampling, testing and release of active substances                                                X

  2.7   Test methods for active substances                                                                X

  2.8   Retain references samples of active substances for at least five (5) years
        or as required by the applicable Regulatory Authorities                                           X

  2.9   Procurement of excipient substances (including certificates of analysis)                          X

  2.10  Storage of excipient substances.                                                                  X

  2.11  Sampling, testing and release of excipient substances                                             X

  2.12  Test methods for excipient substances                                                             X

  2.13  Storage of excipient retain samples at least five (5) years after the
        manufacture date of product containing the raw material                                           X

  2.14  Process Validation Protocol Development                                                           X

  2.15  Process Validation Implementation and Report                                                      X

<PAGE>

  2.16  Cleaning Validation Protocol Development                                                          X

  2.17  Cleaning Validation Implementation and Report                                                     X

  2.18  Bill of Materials for Manufacture                                                                 X

  2.19  Manufacturing Instructions (Production Operating Instructions)                                    X

  2.20  Production of material (including batch documentation)                                            X

  2.21  In-process control instructions                                                                   X

  2.22  In-process control testing (including documentation)                                              X

  2.23  Sampling and testing of bulk material                                                             X

  2.24  Test method for bulk material                                                                     X

  2.25  Test method qualification                                                                         X

  2.26  Retain reference samples of bulk material for five (5) years or in
        accordance with the applicable Regulatory Authorities regulation                                  X

  2.27  Specifications for bulk packaging materials                                                       X

  2.28  Procurement of bulk packaging materials                                                           X

  2.29  Test Methods for bulk packaging materials                                                         X

  2.30  Samaritan to supply information re shipment of Finished Product Capsules           X

                                                                                       Contract       Contract
                                                                                         Giver         Acceptor
        RESPONSIBILITIES                                                              (Samaritan)    (Pharmaplaz)
        ----------------                                                            --------------  ------------
  3.0   TESTING AND RELEASE OF PRODUCT

  3.1   Sampling, testing and stability of finished product                                               X

        Supply of Certificate of Analysis upon satisfactory review of production and
        quality control records.                                                                          X

<PAGE>

  3.2   Release for packaging/trial of finished product by a Qualified Person (or
        equivalent responsible person)                                                                    X

  3.3   Samaritan to send Pharmaplaz a signed letter to indicate that product is
        released for further shipment. Until the letter is received, the product
        cannot be shipped.                                                                 X

  3.4   Customer Complaints                                                                               X
        Collecting and logging                                                                            X
        Investigation and issue of reports to Samaritan                                                   X
        Follow-up corrective action                                                                       X
        Response to customer                                                                              X

  3.5   Annual product review                                                                             X

  3.6   Product recall                                                                     X
        Perform any investigations as requested by Samaritan in relation to recall
        activities                                                                                        X

  3.7   Liaison with Regulatory Authorities for clinical trial items, Marketing
        Authorization                                                                      X

  3.8   Prepare stability program                                                                         X

  3.9   Approval of stability program                                                      X

  3.10  Perform stability testing, provide reports on same                                                X

                                                                                        Contract       Contract
                                                                                         Giver         Acceptor
        RESPONSIBILITIES                                                              (Samaritan)    (Pharmaplaz)
        ----------------                                                            --------------  ------------
  4.0   GENERAL

  4.1   Facility Design, Build and Validation                                                             X

</TABLE>

1.7      Full Scale Manufacturing Development Committee.

          (a)  Establishment.   Upon  written  notification  from  Samaritan  to
               Pharmaplaz  that  Samaritan  desires  to enter  into a FSMC for a
               particular  drug,  the  Parties  will  form a  joint  product  to
               coordinate  certain  activities  under a FSMC.  Each Party  shall
               appoint a  delegation  of two (or three if the  Parties so agree)
               senior  representatives  to serve on the  Development  Committee,
               each of which shall be  authorized  by its  principal to transact

<PAGE>

               the  business  of  the  Development   Committee.   All  decisions
               regarding  those  matters  which are  expressly  stated to be the
               responsibility of the Development  Committee under Article 1.7(b)
               will be made by unanimous agreement of the Development Committee,
               and if the Development  Committee  cannot reach such agreement on
               any matter it shall be referred to the C.E.O.  of  Samaritan  for
               final  decision.  The  Development  Committee shall meet at least
               quarterly and such meetings may be conducted  either in person or
               telephonically.

          (b)  General  Functions.  The functions of the  Development  Committee
               shall be:

               (i)  To prepare for and coordinate the efficient  introduction of
                    drug which is the subject of the FSMC in the  periods  prior
                    to and after Regulatory Authority approval;

               (ii) To coordinate manufacturing and supply activities under this
                    Agreement, including the activities of suppliers of Products
                    other than Pharmaplaz;

               (iii)To provide for and  optimize  the  exchange  of  information
                    concerning the respective development activities relating to
                    manufacturing    processes,    preclinical    and   clinical
                    development,   and  further   indications  for  the  Product
                    improvements,  and new Inventions subject to a FSMC, as well
                    as other Beta Molecules;

               (iv) To coordinate and monitor such development activity;

               (v)  To  review  and  coordinate   marketing  and   manufacturing
                    strategies of each Party hereto; and

               (vi) To engage in such further exchanges of information and joint
                    planning   activities,   and  to  appoint   task  forces  or
                    subcommittees, as the Parties shall find convenient.

1.8      This contract and all amendments are subject to Public Law 96-517,
         Public Law 98-620, and Samaritan's obligations under agreements with
         other collaborators of research such as Georgetown University. Any
         right granted in this Agreement greater than that permitted under
         Public Law 96-517, Public Law 98-620, and Samaritan's obligations under
         agreements with other collaborators of research such as Georgetown
         University shall be subject to modification as may be required to
         conform to the provisions of those statutes or contractual and
         licensing obligations. All rights reserved by the United States
         Government and others under Public Law 96-517, and Public Law 98-620,
         shall remain and shall in no way be affected by this Agreement.

<PAGE>

2. Inspections and Audits.

2.1      Regulatory Inspections. Authorized representatives of Samaritan may,
         upon reasonable advance notice, and representatives of any Regulatory
         Authorities having regulatory authority over the subject matter herein,
         may, at reasonable times, examine and inspect the facilities being used
         to conduct a Study, including the Participating Institutions, and
         review all records, procedures and other materials (including Case
         Report Forms and patient medical records to the extent allowed by the
         informed consent document or other legal disclosure authorization)
         related to a Study, and have access to the Principal Investigator and
         the Participating Investigators to discuss a Study. If a Participating
         Institution is found deficient in any manner by Samaritan, Pharmaplaz,
         an IRB, or a Regulatory Authority, and reasonable efforts to correct
         the deficiency are ineffectual, Pharmaplaz shall either terminate that
         Institution's continued participation in the Study or take such
         corrective actions as may be agreed between Samaritan and Pharmaplaz.
         It is further agreed that if Pharmaplaz is notified that a Study is to
         be the subject of an audit, Pharmaplaz shall promptly inform Samaritan.
         If a formal response to any audit is required, Pharmaplaz agrees to
         permit representatives of Samaritan to review and comment on such
         response. Any liability or risk which results, either directly or
         indirectly from the deficiencies discussed herein, shall be the sole
         responsibility of Pharmaplaz and Pharmaplaz shall indemnify and hold
         Samaritan harmless.

2.2      Compliance Audits. Samaritan has the right to conduct on-site Study
         compliance audits of Pharmaplaz and Participating Institutions
         monitored by Pharmaplaz at mutually agreed upon times. Audits shall be
         at no additional cost to Samaritan provided such audits are at mutually
         agreed upon intervals and do not significantly alter Pharmaplaz's
         ability to meet any deadlines delineated in this Agreement or Addendum.
         Samaritan may only request records or documents that are within the
         scope of the documents Pharmaplaz or the Participating Institution is
         required to maintain under the obligations of this Agreement, Addendum
         or under applicable regulations as promulgated and amended from time to
         time by the Regulatory Authorities.

3. Representations and Warranties of Pharmaplaz. Pharmaplaz further represents,
   warrants and covenants that it:

o        is complying with cGMP's (21 CFR Parts 210 & 211);

o        has not been debarred under Article 306 of the Federal Food, Drug and
         Cosmetic Act, 21 U.S.C. ss.335a(a) or (b) or any related E.U. laws and
         regulations;

o        has not received notice of any cGMP violations;

o        has not been issued a FDA Form-483;

o        has not entered into any other agreements which would inhibit its
         performance hereunder;

o        has not been subject to any seizure activity by any Regulatory
         Authorities;

o        has not entered into any Consent Decrees which effect or restrict its
         ability to perform hereunder;

<PAGE>

o        has not been ordered a shut-down by a governmental agency; or

o        has not been investigated for non-compliance of a cGMP issue.

         In the event that Pharmaplaz has an event described herein
         (collectively known as "Non-Compliant"), Pharmaplaz agrees to notify
         Samaritan immediately. Pharmaplaz is solely responsible for the
         selection and engagement of entities to perform a Study and other
         services to the extent that Pharmaplaz is allowed by the terms of this
         Agreement to subcontract for those services. Pharmaplaz hereby
         certifies that it has not and shall not use, in any capacity related to
         a Study, the services of any individual, corporation, partnership, or
         association which is Non-Compliant. In the event that Pharmaplaz
         becomes aware of or receives notice of the Non-Compliance of any
         individual, corporation, partnership, or association providing services
         to Pharmaplaz which relates to the research conducted under this
         Agreement, Pharmaplaz agrees to notify Samaritan immediately. Failure
         to give notice within 12 hours of knowledge of a Non-Compliant event or
         failure to correct a Non-Compliant event within five (5) days gives
         Samaritan the right to cancel this contract without penalty or further
         obligation and Pharmaplaz releases and discharges Samaritan for all
         claims, liabilities, demands, and causes of action known or unknown,
         fixed or contingent, which Pharmaplaz may have or claim to have against
         Samaritan as a result of this termination and does hereby agree not to
         file a lawsuit to assert such claims.

4. Payment.

4.1      Amount. Samaritan shall compensate Pharmaplaz according to the Budget
         and Payment Schedule attached to each Addendum. Samaritan can make
         payments in U.S. Dollars or in the national currency for Pharmaplaz or
         its subcontractors. Each invoice shall contain the amount of the
         invoice in U.S. Dollars, Euro Dollars and if subcontracted than in the
         subcontractors national currency. If the invoice is in currencies other
         than U.S. Dollars, the amount shall be calculated using the appropriate
         foreign exchange spot rate for such currency quoted by the Wall Street
         Journal, on the close of business on the last banking day of each
         calendar quarter.

4.2      Payee. Any payment due from Samaritan set forth in the Addendum shall
         be tendered in the form of a check payable to Pharmaplaz at one of the
         following addresses, or such alternative address as may be stated in an
         Addendum.

4.3      Delays. In the event of Force Majeure (as defined in Section 23 herein)
         the Parties agree to revise the Budget and Payment Schedule as
         necessary to reflect cost increases or decreases resulting from said
         Force Majeure.

4.4      Payment of Invoices. Samaritan shall be responsible for paying invoices
         within thirty (30) calendar days of receipt. Samaritan shall notify
         Pharmaplaz of any disputed invoices with an invoice dispute notice
         within 10 days of the receipt of invoices and shall pay any undisputed
         amounts as set forth above. If Samaritan pays undisputed amounts as set
         forth above, Pharmaplaz shall continue to conduct research during which
         time the Parties shall use best efforts to resolve the disputed amount.
         In the event that the Parties cannot resolve the disputed amount within
         twenty (20) calendar days of Pharmaplaz receiving the invoice dispute
         notice from Samaritan, Pharmaplaz shall have the right to stop work
         upon ten (10) calendar days written notice to Samaritan. Both Parties
         agree to continue good faith efforts to resolve the dispute prior to
         such stoppage of work.

<PAGE>

4.5      Default. Should Samaritan or Pharmaplaz default on any of its
         obligations, each shall be responsible for their own attorney's fees
         and all other reasonable expenses incurred in exercising any of its
         rights and remedies upon default.

5. Modifications and Amendments.

                  This Agreement or an Addendum may be amended from time to time
         upon the written agreement of the Parties. The Parties agree to exert
         good faith efforts to incorporate any revisions required by law, FDA or
         other international health authorities. Any changes to a Scope of Work
         or Budget and/or Payment Schedule in an Addendum, after an Addendum is
         executed, shall be incorporated into the Addendum by means of a change
         order ("Change Order"). Pharmaplaz shall be under no obligation to
         commence work on any change to the scope of work until the change order
         is executed.

6. Data.

6.1      Clinical Data. All clinical data, including case report forms and other
         relevant information generated during a Study shall be promptly and
         fully disclosed to Samaritan and shall be freely accessible to and
         usable by Samaritan and shall be deemed the property of Samaritan.
         Samaritan shall ensure that Pharmaplaz receives data transfers and/or a
         final data set of any Study data developed and/or maintained by
         Samaritan or any third party in privity of contract with Samaritan,
         including but not limited to a pharmacy and/or randomization vendor, as
         required for Pharmaplaz to fulfill its obligations and exercise its
         rights pursuant to a Addendum and related Scope of Work. Pharmaplaz
         shall maintain all such clinical data for the duration of this
         Agreement and for a five (5) year period after termination. Upon
         termination Pharmaplaz shall, if so requested by Samaritan, provide to
         Samaritan a complete copy of all such clinical data. All such clinical
         data shall be stored in a safe manner so as to protect it from
         inadvertent or intentional destruction.

6.2      Regulatory Filings. Any and all findings obtained as a result of a
         Study shall be communicated to Samaritan which shall be free to
         incorporate such findings in any regulatory filing concerning the
         Products. Pharmaplaz and Principal Investigators understand and agree
         that they shall have no ownership, license or access rights in, or to,
         any inventions which result, either directly or indirectly, from the
         relationship created hereunder or any such regulatory filings solely
         based upon the inclusion of such findings therein, nor shall they
         acquire any interest whatsoever in the Products, improvements or new
         Inventions as a result of performing a Study or performing its
         obligations hereunder.

<PAGE>

7. Product Transfer Agreement.

7.1      Samaritan retains ownership of the Product, any improvements thereto or
         new Inventions, including any Product contained or incorporated in
         Modifications.

7.2      Pharmaplaz and Pharmaplaz Scientists agree that the Product:

          (a)  is to be used solely for Samaritan's research purposes;

          (b)  will not be used in human subjects,  in clinical  trials,  or for
               diagnostic  purposes involving human subjects without the written
               consent of Samaritan;

          (c)  employees   shall   agree  to  execute  a   Confidentiality   and
               Nondisclosure   Statement   evidencing   their   intent  to  keep
               information related to the Product and any subsequent  inventions
               thereto confidential;

          (d)  is to be used  only by the  Pharmaplaz  organization  and only in
               Pharmaplaz  Scientist's  laboratory  under the  direction  of the
               Pharmaplaz's  Principal  Investigator  or  others  working  under
               his/her direct supervision;

          (e)  expressly  acknowledge  that any  improvements  to the Product or
               inventions which result, either directly or indirectly,  from any
               Studies  or  manufacturing   process  is  the  sole  property  of
               Samaritan and to the extent necessary, Pharmaplaz, and Pharmaplaz
               Scientists   will  execute  any  and  all   necessary   documents
               evidencing Samaritan's ownership; and

          (f)  will not be  transferred  to anyone  else  within the  Pharmaplaz
               organization without the prior written consent of Samaritan.

7.3      Pharmaplaz and the Pharmaplaz Principal Investigator agree to refer to
         Samaritan for any request for the Product from anyone other than those
         persons working under the Pharmaplaz Scientist's direct supervision. To
         the extent supplies are available, Pharmaplaz or Pharmaplaz Scientist's
         agrees to make the Product available, under another agreement having
         terms consistent with the terms of this Agreement, to other scientists
         at Nonprofit Organization(s) designated by Samaritan who wish to
         replicate the Pharmaplaz Scientist's research; provided that such other
         scientists reimburse Pharmaplaz for any costs relating to the
         preparation and distribution of the Product.

7.4      Without written consent from Samaritan, Pharmaplaz and/or the
         Pharmaplaz Principal Investigator may NOT provide Modifications for
         commercial purposes. It is recognized by Pharmaplaz that such
         commercial purposes may require a commercial license from Samaritan and
         Samaritan has no obligation to grant a commercial license to its
         ownership interest in the Product incorporated in the Modifications.

<PAGE>

7.5      Pharmaplaz acknowledges that the Product is or may be the subject of a
         patent application. Except as provided in this Agreement, no express or
         implied licenses or other rights are provided to the Pharmaplaz under
         any patents, patent applications, trade secrets or other proprietary
         rights of Samaritan, including any altered forms of the Product made by
         Samaritan. In particular, no express or implied licenses or other
         rights are provided to use the material, modifications, or any related
         patents of Samaritan for commercial purposes.

7.6      If Pharmaplaz desires to use or license the Product, improvements
         thereto, new Inventions or Modifications for commercial purposes, it is
         understood by Pharmaplaz that Samaritan shall have no obligation to
         grant such a license to Pharmaplaz, and may grant exclusive or
         non-exclusive commercial licenses to others, or sell or assign all or
         part of the rights in the material to any third party(ies), subject to
         any pre-existing rights held by others and obligations to the Federal
         Government.
7.7      Any Product delivered pursuant to this Agreement is understood to be
         experimental in nature and may have hazardous properties. TO THE EXTENT
         APPLICABLE, SAMARITAN MAKES NO REPRESENTATIONS AND EXTENDS NO
         WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED AS TO THE SAFETY,
         EFFICIENCY OR HAZARDOUS NATURE OF THE PRODUCT. THERE ARE NO EXPRESS OR
         IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
         PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT,
         COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

7.8      In no event shall Samaritan be liable for any use of the Product by
         Pharmaplaz or by others, either on Pharmaplaz's behalf or on behalf of
         those who receive the Product from Pharmaplaz. To the extent and in the
         manner provided for by applicable law, Pharmaplaz shall indemnify and
         hold Samaritan harmless from any and all claims, loss, liability,
         damages, and expenses (including attorneys' fees) that may result from
         Pharmaplaz's use, storage, handling, or disposal of the Product, and
         which result from its relationship with Study sites and Study
         investigators, except to the extent permitted by law when caused by the
         gross negligence or willful misconduct of Samaritan.

7.9      This agreement shall not be interpreted to prevent or delay publication
         of research findings resulting from the use of the Product or the
         Modifications. Pharmaplaz's Principal Investigator agrees to provide
         appropriate acknowledgement of the source of the Product in all
         publications and further agrees not to publish any materials, articles
         or statements concerning the Product, improvements thereto or new
         Inventions until such time as Samaritan has been able to file the
         appropriate documents with the United States Patent Office or the
         corollary agency in the EU or other countries.

7.10     Pharmaplaz agrees to use the Product in compliance with all applicable
         statutes and regulations, including Public Health Service and National
         Institutes of Health regulations and guidelines such as, for example,
         those relating to research involving the use of animals or recombinant
         DNA.

<PAGE>

8. Inventions.

8.1      Prior Inventions. It is recognized and understood that certain existing
         inventions and technologies are the separate property of Pharmaplaz or
         Samaritan and are not affected by this Agreement or any Addendum, and
         neither Party shall have any claims to or rights in such prior,
         separate inventions and technologies, or improvements thereto, except
         only to the extent required for the conduct of the Study.

8.2      Title.  Ownership of new Inventions, improvements, developments, or
         discoveries arising out of the Study (hereinafter "Invention") shall be
         the property of Samaritan.

8.3      Assignment of Rights. Pharmaplaz hereby grants Samaritan, without fee
         other than the consideration of the Study sponsored herein and the
         reimbursement of all patent expenses related to the Invention incurred
         by Pharmaplaz prior to and during the Study, an assignment from
         Pharmaplaz, within ten (10) business days of the request of Samaritan,
         with respect to any new Invention, improvements to the Products or
         Modifications in the form and substance as set forth as Appendix B
         attached hereto.

9. Confidential Information.

9.1      Confidential Information. Confidential Information shall mean all
         information provided by one Party to the other whether or not clearly
         identified as "Confidential" by the transmitting Party at the time of
         disclosure. Specifically excepted from Confidential Information is all
         information that: (a) was previously known by the receiving Party; (b)
         is publicly disclosed except by breach of this Agreement either prior
         to or subsequent to the receiving Party's receipt of such information;
         (c) is rightfully received by the receiving Party from a third party
         without an express obligation of confidence; or (d) is independently
         developed by personnel of the receiving Party without use of or
         reliance upon Confidential Information of the other Party.

9.2      Nondisclosure. Subject to the provisions of this Agreement, the
         receiving Party shall not disclose Confidential Information of the
         Disclosing Party to any third party without prior written authorization
         from the disclosing Party. This provision shall remain in effect for
         three (3) years following the termination of this Agreement.

9.3      Patient Information. Each Party shall be provided with patient
         information as allowed by law and the executed patient consent and
         authorization documents and shall maintain the confidentiality of all
         such patient information, unless specifically required to disclose such
         information by law.

9.4      Legally Required Disclosure. Nothing set forth herein shall operate to
         prohibit or prevent a Party from disclosing Confidential Information
         pursuant to any judicial or government request, requirement or order,
         provided that the disclosing Party takes reasonable steps to provide
         the other Party with sufficient prior notice in order to allow the
         other Party to contest such request, requirement or order.

<PAGE>

10. Publication.

                   Pharmaplaz recognizes the importance of communicating medical
         research and scientific data and its obligations to patients enrolled
         in a Study and therefore, encourages publication of such material in
         reputable scientific journals and at professional and/or academic
         seminars or conferences. Samaritan shall consider in good faith all
         comments received from Pharmaplaz during the review period; provided,
         however, nothing in this Agreement shall prohibit Samaritan from the
         publication of all information necessary for the accurate
         interpretation and presentation of said medical research and scientific
         data. If Pharmaplaz determines that the proposed publication contains
         patentable subject matter which requires protection, Pharmaplaz may
         require the delay of publication for an additional period not to exceed
         ninety (90) calendar days for the purpose of filing patent
         applications. Samaritan and the Principal Investigators shall give
         Pharmaplaz and/or Pharmaplaz's personnel appropriate credit in the
         publication for any direct contribution made by them, and shall
         acknowledge Pharmaplaz's support in all publications and presentations.
         This publication provision is subject to Samaritan's acknowledged right
         to protect its intellectual property before publication.

11. Use of Name.

                   Pharmaplaz and Samaritan shall obtain the prior written
         permission from each other before using the name, symbols and/or marks
         of the other in any form of advertising in connection with this
         Agreement. This shall not include legally required disclosure by
         Pharmaplaz or Samaritan that identifies the existence of the Agreement,
         reports generated in the normal course of business by Pharmaplaz or
         Samaritan, or where acknowledgment of the Agreement or Invention
         Assignment is required by the guidelines of a scientific publication or
         organization. Samaritan may use the name of Pharmaplaz in connection
         with its status as a Contract Manufacturing Organization or scientific
         advisor to Samaritan. Pharmaplaz may use the name of Samaritan in
         connection with Pharmaplaz's status as a Contract Manufacturing
         Organization or scientific advisor to Samaritan. Pharmaplaz
         acknowledges that Samaritan is a publicly traded company and shall be
         required by law and applicable regulations to make disclosures relating
         to this Agreement or Invention Assignments.

12. Indemnification.

12.1     Indemnification by Pharmaplaz. Pharmaplaz agrees to indemnify, hold
         harmless and defend Samaritan, its trustees, officers, employees, and
         agents from and against any and all claims, suits, losses, damages,
         costs, fees, expenses (including attorneys' fees), and other
         liabilities asserted by third parties, both government and
         non-government, resulting from or arising out of this Agreement or any
         Addendum or research program carried out pursuant to this Agreement
         (the "Liabilities"), including, but not limited to, any liabilities
         resulting from the negligent and willful misconduct of any Participant
         Institution or Investigators. Notwithstanding the forgoing, Pharmaplaz
         shall not be liable to Samaritan to the extent the Liabilities are the
         result of Samaritan's willful misconduct in connection with a Study.

<PAGE>

12.2     Indemnification Process. A Party seeking indemnification hereunder
         shall give notice to the other Party promptly upon receipt of written
         notice of the potential claim. The Party seeking indemnification shall
         permit the indemnifying party to assume the defense and/or disposition
         of any such claim or related litigation, provided that counsel is
         reasonably acceptable to the party seeking indemnification. The Party
         seeking indemnification shall cooperate with the indemnifying Party in
         all reasonable respects with respect to the defense of any such claim,
         with the out-of-pocket costs of the Party seeking indemnification to be
         reimbursed by the indemnifying Party.

13. Insurance.

                   Pharmaplaz hereto warrant that they shall maintain during the
         term hereof policies of liability insurance with minimum coverage as
         follows: Pharmaplaz represents that it carries Comprehensive or
         Commercial Form General and Professional Liability Insurance or
         equivalent program of self-insurance with limits not less than three
         million dollars ($3,000,000) per occurrence combined single limit and
         ten million dollars ($10,000,000) annual aggregate. If such insurance
         or program of self-insurance is written on a claim-made form, coverage
         shall survive for a period of not less than three (3) years following
         termination of the Agreement. Coverage shall provide for a retroactive
         date of placement coinciding with or prior to the effective date of
         this Agreement. Pharmaplaz represent that it will obtain Product and
         Completed Operations Liability Insurance or equivalent program of
         self-insurance with limits not less than the loss to Samaritan under
         each Addendum. Pharmaplaz represents that it carries Transit Insurance
         Coverage and will inform its insurance broker of shipments made to
         Samaritan. Samaritan Pharmaceuticals shall be an additional named
         insured and/or loss payee, as appropriate, on all of the above policies
         and shall annually be provided with confirmation that these coverages
         are being maintained. Pharmaplaz agrees to furnish to Samaritan a
         certificate of insurance or evidence of self-insurance acceptable to
         Samaritan indicating the required coverage stated in the above
         paragraph.

14. Compliance with Law.

                   Each Study shall be conducted in compliance with all of the
         applicable Regulatory Authorities' laws, regulations and guidelines,
         including, without limitation, the Health Insurance Portability and
         Accountability Act ("HIPAA") of 1996 and all requirements imposed by
         legally constituted IRBs. Pharmaplaz agrees to collect, use and
         disclose information with respect to any Study subject only in
         accordance with the informed consents and legal disclosure
         authorizations obtained from such Study subject as part of the Study,
         unless otherwise required by law. Pharmaplaz further agrees that each
         informed consent and authorization shall include the express consent of
         the Study participant to use all data obtained from that Study patient
         in any and all studies going forward and that Study patient expressly
         acknowledges that all information it may receive during the course of
         the Study related to the Product is proprietary to Samaritan.

<PAGE>

15. Term and Termination.

15.1     Term. The term of this Agreement shall commence as of the Effective
         Date and terminate upon the later of five (5) years from the Effective
         Date or completion of all research pursuant to all Addenda hereto,
         unless terminated sooner in accordance with the terms herein.

15.2     Termination.  This Agreement or any Addendum hereto may be terminated
         for any reason by either Party upon ninety (90) days prior written
         notice to the other Party.

15.3     Addendum Termination.  Notwithstanding the foregoing, any Addendum
         hereto may be terminated immediately by written notice, in the
         following circumstances:

          (a)  Authorization and approval to perform a Study is withdrawn by the
               applicable Regulatory Authority;

          (b)  Animal,  human, or toxicological test results,  in the reasonable
               determination of Samaritan,  support immediate termination of the
               Study;

          (c)  The emergence of adverse events with a compound administered in a
               Study  is  of  such  magnitude  or  significance   that,  in  the
               reasonable determination of Samaritan or a Data Safety Monitoring
               Board, supports immediate termination of the Study; and

          (d)  A  material  event  adversely  affecting  Samaritan's  ability to
               finance the Study.

15.4     Termination for Breach. This Agreement or any Addendum may be
         terminated by either party upon the occurrence of any material breach
         or default by the other Party, provided that the breaching or
         defaulting party shall be given not less than sixty (60) days prior
         written notice and the opportunity to cure the breach or default during
         such period.

15.5     Wind Down Plan Upon Termination. Both Pharmaplaz and Samaritan
         recognize that early termination of this Master Agreement or any
         Addendum requires both discussion and coordination between the Parties
         to ensure patient safety, continuity of treatment, if appropriate, and
         compliance with all applicable regulations. Upon early termination of
         this Master Agreement or any Addendum hereto, the Parties shall
         cooperate to provide for an orderly cessation of the Research. Each
         Party further agrees to take no action or forego taking action if such
         action or forbearance would in any manner jeopardize patient safety or
         the utility, quality or integrity of the Study or violate or cause the
         other Party to violate any applicable laws. In addition, Pharmaplaz
         shall conduct such Research activities as are reasonably necessary in
         connection with the orderly wind-down of the Study or the transfer of
         Pharmaplaz's responsibilities to Samaritan or its designee. Based upon
         Samaritan's written instructions regarding the scope of Research
         activities to be conducted by Pharmaplaz in connection with termination
         of the Study, to be delivered to Pharmaplaz as soon as possible after
         notice of termination is received, Pharmaplaz shall submit to Samaritan
         a wind-down, close out, or transfer plan to accomplish the tasks or
         Research identified by Samaritan's written instructions together with a
         budget to be mutually agreed in writing ("Plan").

<PAGE>

15.6     Handling Data Upon Termination. The Parties agree that the transfer of
         the Study data and outstanding reports are critically important to both
         Parties. The Plan shall include the procedures and responsibilities of
         each Party including but not limited to the orderly collection of all
         patient data outstanding at participating sites, data analysis and
         entry of such data into the Study database, and any manuscript
         resulting therefrom.

16. Governing Law.

                  The validity, interpretation and performance of this Agreement
         and Addenda shall be governed and construed in accordance with the laws
         of the State of Nevada regardless of choice of law rules.

17. Arbitration.

                   The Parties agree to attempt to resolve promptly any dispute
         arising out of or relating to this Agreement by good faith negotiation;
         provided, however, if such attempts at dispute resolution shall fail,
         disputes relating to the terms and conditions of this Agreement shall
         be exclusively resolved, upon written request by either Party, by final
         and binding arbitration in Las Vegas, Nevada, pursuant to the
         commercial arbitration rules of the American Arbitration Association,
         in accordance with the following procedures:

          (a)  The arbitration tribunal shall consist of three arbitrators.  The
               Parties shall respectively nominate one arbitrator in the request
               for arbitration and one arbitrator in the answer thereto, and the
               two  arbitrators  so named  will  then  jointly  appoint  a third
               arbitrator as chairperson of the arbitration tribunal.

          (b)  The  decision  of the  arbitration  tribunal  shall be final  and
               binding upon the Parties hereto,  and judgment upon such decision
               may be entered in any competent court for juridical acceptance of
               such an award and order of enforcement. Each Party hereby submits
               itself to the  courts of the place of  arbitration,  but only for
               the  entry  of  judgment  with  respect  to the  decision  of the
               arbitrators hereunder.

          (c)  The parties agree that each party shall have the right to receive
               from  the  other  party  answers  to  twenty-five   (25)  written
               interrogatories,  and  to  take  five  (5)  oral  depositions  of
               selected  witnesses.  The arbitral  tribunal shall make a written
               record  based  on  its  award.  The  arbitral   tribunal  is  not
               authorized to award costs and  attorneys'  fees to the prevailing
               party as part of its award.  Any award of the  arbitral  tribunal
               shall be binding and enforceable against the parties in any court
               of competent jurisdiction, and the parties hereby waive any right
               to appeal  such  award on the  merits or to  challenge  the award
               except on the grounds expressly  provided for in Article V of the
               1958 New York  Convention on the  Recognition  and Enforcement of
               Foreign Arbitral Awards.  Notwithstanding the foregoing agreement
               to  arbitrate,  the parties  expressly  reserve the right to seek
               provisional relief from a Nevada Court of competent  jurisdiction
               to preserve their respective rights pending arbitration.

<PAGE>

18. Relationship of the Parties.

                   Pharmaplaz, the Principal Investigator and Samaritan, under
         this Agreement and any Addendum, shall be that of an independent
         contractors and not an agent, joint venture, or partner of the other.
         No Party hereto shall have, or shall represent that it has, any power,
         right or authority to bind the other Party hereto to any obligation or
         liability without express authorization from such other Party.

19. Similar Research.

                   Nothing in this Agreement or an Addendum shall be construed
         to limit the freedom of Samaritan or its researchers who are
         participants under this Agreement, from engaging in similar research
         made under other grants, contracts or agreements with parties other
         than Pharmaplaz.

20. Force Majeure.

                   If either Party hereto shall be delayed or hindered in, or
         prevented from, the performance of any act required hereunder for any
         reason beyond such Parties direct control, including but not limited
         to, strike, lockouts, labor troubles, governmental or judicial actions
         or orders, riots, insurrections, war, acts of God, inclement weather or
         other reason beyond the Party's control (a "Disability") then such
         Party's performance shall be excused for the period of the Disability.
         Any Study timelines affected by a Disability shall be extended for a
         period equal to the delay and any affected Budget shall be adjusted to
         account for cost increases or decreases resulting from the Disability.
         The Party affected by the Disability shall notify the other Party of
         such Disability as provided for herein.

21. Entire Agreement.

                   This Agreement and Addenda attached hereto constitute the
         full and complete understanding of the Parties hereto with respect to
         the subject matter hereof and supersedes all prior understandings and
         agreements with respect to such subject matter. In the event of a
         conflict between an Addendum and the terms in this Agreement, the
         provisions of the Addendum shall govern regarding that particular
         Study. Any handwritten modifications to this Agreement or an Addendum
         shall be null and void unless such modifications are initialed by both
         Parties.

22. No Waivers.

                   No delay or omission by a Party hereto to exercise any right
         under this Agreement or an Addendum shall impair any such right or
         power or be construed to be a waiver thereof. A waiver by any of the
         Parties hereto of any of the covenants, conditions or agreements herein
         contained shall not be construed to be a waiver of any succeeding
         breach thereof or of any covenant, condition or agreement herein
         contained. No waiver or discharge of any provisions of this Agreement
         or an Addendum shall be valid unless it is in writing and is executed
         by the Party against whom such change or discharge is sought to be
         enforced.

<PAGE>

23. Severability.

                   If a judicial determination is made that any of the
         provisions contained in this Agreement or an Addendum constitute an
         unreasonable restriction against a Party or are otherwise
         unenforceable, such provision or provisions shall be rendered void or
         invalid only to the extent that such judicial determination finds such
         provision or provisions to be unreasonable or otherwise unenforceable,
         and the remainder of this Agreement or a Addendum shall remain
         operative and in full force and effect.

24. Headings.

                   The headings contained in this Agreement do not form a
         substantive part of this Agreement and shall not be construed to limit
         or otherwise modify its provisions.

25. Notices.

                   Any notice or other communication required or permitted under
         the Agreement shall be in writing and shall be deemed given as of the
         date it is received by the receiving Party. Notice shall be given to
         the Parties at the addresses listed below, or such alternative address
         as may be provided by one Party to the other in writing:

                  If to Pharmaplaz:

                  President
                  Pharmaplaz, Ltd.
                  Daneswell Business Park,
                  Monksland, Athlone,
                  County Roscommon Ireland

                  If to Samaritan:

                  Chief Executive Officer
                  Samaritan Pharmaceuticals
                  101 Convention Center Drive
                  Suite 310
                  Las Vegas, NV 89109

<PAGE>

         IN WITNESS WHEREOF, this Agreement is entered into as of the date first
written above.

Samaritan Pharmaceuticals                            Pharmaplaz

By:  /s/ Janet Greeson, Ph.D.                        By:  /s/ Michael J . Macken
Name: Janet Greeson, Ph.D.                           Name: Michael J. Macken
Title: C.E.O.                                        Title: C.E.O
Date: 5 October 2004                                 Date: 5 October 2004

 Samaritan Pharmaceuticals                           Pharmaplaz

By: /s/ Eugene Boyle                                 By:  /s/ Patricia M. Watson
Name: Eugene Boyle                                   Name: Patricia M. Watson
Title: C.FO.                                         Title: General Manager
Date: 5 October 2004                                 Date: 5 October 2004

<PAGE>

                                   Appendix A

                                 Addendum # ___

Study Title:

Principal Investigator:                                   Protocol Number:

This Agreement is entered into by and between Pharmaplaz Ltd. ("Pharmaplaz") and
Samaritan Pharmaceuticals, Inc. ("Samaritan") as an Addendum to the Master
Clinical Research Agreement effective as of ________, 200__ and to establish
specific terms for the conduct of the above referenced Study.

1. Description of the Study.

         Pharmaplaz shall coordinate the Study at Pharmaplaz and at the Clinical
         Sites participating in the Study as defined herein in accordance with
         the Protocol (Exhibit A) and the Scope of Work (Exhibit B) which are
         attached hereto and incorporated herein and which fully detail the
         research activities and responsibilities to be undertaken.

2. Personnel.

         The Principal Investigator for this Study shall be ___________________.

3. Study Product.

         Pharmaplaz shall provide appropriate investigational product for use in
         the Study as designated by Samaritan.

4. Awards and Payments.

         Samaritan agrees to reimburse Pharmaplaz for expenses incurred in the
         conduct of the Study in accordance with the Budget and Payment Schedule
         attached hereto and incorporated herein as Exhibits C and D.

5. Transfer of Obligations.

         In accordance with 21 CFR ss. 312.52, Samaritan hereby transfers to
         Pharmaplaz those obligations set forth in Exhibit B.

6. Effective Date and Term.

         This Addendum shall become effective on _______________ and shall
         continue in effect until completion of the Study or its earlier
         termination in accordance with the Master Clinical Research Agreement.

7. Other:

         (As may be applicable to a particular Study including any necessary
         variations on the terms of the Master Research Agreement).

AGREED:

Samaritan Pharmaceuticals, Inc.               Pharmaplaz Ltd.

By: _____________________________             By: ______________________________
     Name:________________________                Name:_________________________
     Title:_________________________              Title:________________________

Date:____________________________             Date:__________________________
Samaritan Pharmaceuticals, Inc.               Pharmaplaz Ltd.

By: _____________________________             By: ______________________________
     Name:________________________                Name:_________________________
     Title:_________________________             Title:_________________________

Date:____________________________             Date:_____________________________

Acknowledged:

Principal Investigator:___________________________

<PAGE>

                                   Appendix B

                             Assignment of Invention

This ASSIGNMENT of INVENTION is made as of the _______ day of ____________,
20_____ by:

Name and nationality of inventor(s) or person(s) or entity(ies) who own the
Invention Address

____________________________  ________________________________________
____________________________  ________________________________________
____________________________  ________________________________________

(herein "Assignor") and Samaritan Pharmaceuticals, Inc., a Nevada for-profit
corporation (herein the "Samaritan") with a principal office at 101 Convention
Center Drive, Suite 310, Las Vegas, NV 89109.

In consideration of the payment by Samaritan to Assignor of the sum of One
Dollar ($1.00), the receipt of which is hereby acknowledged, and for other good
and valuable consideration, the parties agree as follows:

1.       Assignor hereby sells, assigns and transfers to Samaritan and the
         successors, assigns and legal representatives of Samaritan the entire
         right, title and interest for the United States and its territorial
         possessions and in all foreign countries, including all rights to claim
         priority, in and to any and all improvements which are disclosed in the
         invention entitled:

         Title of Invention

         (herein, the "Invention")

         (Check and complete (a), (b), (c) (d) or (e)) and which is found in

a. [ ] description attached hereto as Appendix A; or

b. [ ] U.S. patent application executed on even date herewith; or

c. [ ] U.S. patent application executed on _____________________________; or

         [ ] To comply with 37 CFR 3.21 for recording of this assignment, I, an
         Assignor signing below, hereby authorize and request my attorney, as
         named in the Declaration and Power of Attorney I executed for this
         invention on the execution date stated above, to insert below the
         filing date and application number when it becomes known.

d.       [ ] U.S. application serial no. _____________ filed on _______________;
         or

<PAGE>

e.       [ ] U.S. patent no. ____________________ issued on ___________________

         [ ] A change of address to which correspondence is to be sent regarding
patent maintenance fees is being sent separately.

         (If assignment is by person to whom the Invention was previously
assigned and this was recorded in PTO add the following)

         Recorded on__________________, Reel_______________, Frame______________

f.       and any legal equivalent thereof in a foreign country, including the
         right to claim priority and, in and to, all Letters Patent to be
         obtained for the Invention by the above application or any
         continuation, division, renewal, or substitute thereof, and as to
         letters patent any reissue or re-examination thereof.

2.       Assignor hereby covenants that no assignment, sale, agreement or
         encumbrance has been or will be made or entered into which would
         conflict with this Assignment.

3.       Assignor further covenants that Samaritan will, upon its request, be
         provided promptly with all pertinent facts and documents relating to
         the Invention and said Letters Patent and legal equivalents as may be
         known and accessible to Assignor and will testify as to the same in any
         interference, litigation or proceeding related thereto and will
         promptly execute and deliver to Samaritan or its legal representatives
         any and all papers, instruments or affidavits required to apply for,
         obtain, maintain, issue and enforce said application, the Invention and
         said Letters Patent and said equivalents thereof which may be necessary
         or desirable to carry out the purposes thereof.

4.       Assignor further agrees to maintain all information relative to the
         Invention, including any ideas, developments, and improvements thereof
         as confidential information of Samaritan. Samaritan shall have total
         discretion as to whether and when a patent application is to be filed
         on the Invention.

5.       Subject to the Patent Policy and Assignor's continued compliance with
         this Assignment, Samaritan shall bear any expense of preparing and
         prosecuting any patent application relating to the Invention.

6.       Any royalty income which may be derived from the Invention shall be
         distributed in accordance with the Patent Policy.

7.       Warranties and Liabilities, Disclaimer of Warranties and Liabilities.

a.       Generally. Each of the parties represents and warrants to the other
         party as follows in this Section 7, and acknowledges that each of the
         following representations and warranties has been relied upon by the
         other party and is material to the other party's decision to enter into
         this Assignment.

<PAGE>

b.       Assignor's Right to Convey. Assignor warrants and represents that
         Assignor is the owner of all right, title and interest in the
         Invention, and that Assignor has the right and authority to grant the
         assignments of rights granted in this Assignment.

c.       No Other Rights of Assignor. Assignor further warrants and represents
         that, with the exception of the rights described in Section 7(b) above,
         Assignor, individually or collectively, does not own, control, or have
         rights to enforce any patent or invention that corresponds to or claims
         any invention relating to the Invention.

d.       No Litigation. Assignor further warrants and represents that there are
         no actions, suits, or proceedings pending against Assignor collectively
         or individually which relate directly or indirectly to the Invention.

e.       General Warranty by Assignor. Assignor further warrants and represents
         that Assignor has the requisite power and authority to execute and
         perform this Assignment and to grant the rights provided for herein to
         Samaritan, and that no obligations under this Assignment conflict with
         any obligation to any present or future employer.

f.       General Warranty by Samaritan. Samaritan warrants and represents that
         it has the requisite power and authority, corporate and otherwise, to
         execute and perform this Assignment.

g.       Limitations. Samaritan warrants and represents that its Assignee(s) of
         the Invention and any patents issuing thereupon shall be required to
         assume responsibility for the design, manufacture, instructions for
         use, quality control and all safety-related activities relating to any
         products made under license, whether or not they incorporate any of
         Assignor's information, technology, and inventions relating to the
         Invention. Assignor shall not be responsible for the products of any
         Assignee(s) of Samaritan pursuant to this Assignment.

h.       Indemnification.  Samaritan shall use its best efforts to obtain from
         its Assignee(s)  of the Invention, an agreement to indemnify, defend,
         and hold harmless Assignor from and against any and all losses, claims,
         damages, liabilities, and expenses (including reasonable attorneys
         fees) arising out of or based upon any bodily injury or property damage
         arising from incorporation of the Invention by said Assignee(s),
         including any and all ideas, developments and improvements of Assignor
         relating thereto and which are incorporated into products of said
         Assignee(s). This indemnification shall be conditioned upon Assignor
         giving said Assignee(s) written notice of any such claim and
         cooperating in the defense of such claim at said Assignee(s) expense.
         Further, Assignor agrees that said Assignee(s)  shall have sole control
         over the defense or settlement of any such claim, action or proceeding,
         and that Assignor shall not enter into any agreement with respect to
         such claim, action or proceeding for which indemnification is or may be
         sought without receipt of said Assignee(s)  prior written approval.

8.       Miscellaneous. The laws of the State of Nevada and of the United States
         of America shall apply to the interpretation of this Assignment.

IN WITNESS WHEREOF, the parties have executed this Assignment on the dates
indicated below.

WARNING: Date of signing must be the same as the date of execution of the
application if item 1(b) was checked above.

ASSIGNOR(S):

Pharmaplaz

By:_______________________________
     Name: Patricia M. Watson
     Title:   General Manager

Date:______________________________

By:_______________________________
     Name: Michael J.Macken
     Title:   C.E.O.

Date:_____________________________

SAMARITAN:

By:_______________________________
     Name: Dr. Janet Greeson
     Title:   President and C.E.O.

Date:______________________________<PAGE>

                                                                    EXHIBIT 10.3

                              EMPLOYMENT AGREEMENT

        THIS AGREEMENT is made as of the 13th day of September, 2004, by and
among ALBANY BANK & TRUST, National Association (the "Bank"), a national bank;
COMMUNITY CAPITAL BANCSHARES, INC., a bank holding company incorporated under
the laws of the State of Georgia (the "Company") (collectively, the Bank and the
Company are referred to hereafter as the "Employer"), and ROBERT E. LEE, a
resident of the State of Georgia (the "Employee").

                                    RECITALS:

        The Employer currently employs the Employee as the President of the Bank
and of the Company pursuant to that certain employment agreement dated August
19, 1998 (the "Employment Agreement").

        The Employer and the Employee desire to amend and restate the Employment
Agreement.

        In consideration of the above premises and the mutual agreements
hereinafter set forth, the parties hereby agree as follows:

1.      DEFINITIONS. Whenever used in this Agreement, the following terms and
their variant forms shall have the meaning set forth below:

        1.1     "AFFILIATE" shall mean any business entity which controls the
Company, is controlled by or is under common control with the Company.

        1.2     "AGREEMENT" shall mean this Agreement and any exhibits
incorporated herein together with any amendments hereto made in the manner
described in this Agreement.

        1.3     "AREA" shall mean the geographic area within the boundaries of
Dougherty and Lee Counties, Georgia and Houston and Lee Counties, Alabama. It is
the express intent of the parties that the Area as defined herein is the area
where the Employee performs services on behalf of the Employer under this
Agreement.

        1.4     "BUSINESS OF THE EMPLOYER" shall mean the business conducted by
the Employer, which is commercial banking.

        1.5     "CAUSE" shall mean:

                1.5.1   With respect to termination by the Employer:

                        (a)     A material breach of the terms of this Agreement
                by the Employee, including, without limitation, failure by the
                Employee to perform his duties and responsibilities in the
                manner and to the extent required under this Agreement, which
                remains uncured after the expiration of thirty (30) days
                following the delivery of written notice of such breach to the
                Employee by the Employer. Such

<PAGE>

                notice shall (i) specifically identify the duties that the Board
                of Directors of either the Bank or the Company believes Employee
                has failed to perform, (ii) state the facts upon which such
                board of directors made such determination, and (iii) be
                approved by a resolution passed by two-thirds (2/3) of the
                directors of such board of directors then in office. The
                Employee shall be provided with an opportunity to address the
                Board of Directors of the Bank or the Company, as applicable,
                prior to such board's approval of a resolution contemplated
                under this Section;

                        (b)     Conduct by the Employee that amounts to fraud,
                dishonesty or willful misconduct in the performance of his
                duties and responsibilities hereunder;

                        (c)     The conviction of the Employee of a felony;

                        (d)     Conduct by the Employee that amounts to gross
                and willful insubordination or inattention to his duties and
                responsibilities hereunder; or

                        (e)     The receipt of any form of notice, written or
                otherwise, that any regulatory agency having jurisdiction over
                the Employer intends to institute any form of formal or informal
                regulatory action against the Employee or the Employer, provided
                that the Board of Directors of either the Company or the Bank
                determines in good faith that such action involves acts or
                omissions by or under the supervision of the Employee or that
                termination of the Employee could materially assist the Employer
                in avoiding or reducing the restrictions or adverse effects to
                the Employer related to the regulatory action.

                1.5.2   With respect to termination by the Employee,

                        (a)     a material diminution in the powers,
                responsibilities or duties of the Employee hereunder;

                        (b)     a material reduction in the Employee's Base
                Salary without the Employee's consent;

                        (c)     relocation of the main office to which the
                Employee reports on a regular basis to a location which is more
                than twenty-five (25) miles from the Employer's main office
                location as of the Effective Date;

                        (d)     a requirement by the Employer that the Employer
                travel unreasonably more than the amount of travel required of
                the Employer as of the Effective Date in connection with the
                performance of his duties for the Employer; or

                        (e)     a material breach of the terms of this Agreement
                by the Employer, which remains uncured after the expiration of
                thirty (30) days following the delivery of written notice of
                such breach to the Employer by the Employee.

                                      -2-
<PAGE>

        1.6     "CHANGE IN CONTROL" means any one of the following events:

                        (a)     the acquisition by any person or persons acting
                in concert of the then outstanding voting securities of either
                the Bank or the Company, if, after the transaction, the
                acquiring person (or persons) owns, controls or holds with power
                to vote twenty-five percent (25%) or more of any class of voting
                securities of either the Bank or the Company, as the case may
                be, or such other transaction as may be described under 12
                C.F.R. Section 225.41(c)(1) or any successor thereto;

                        (b)     within any twelve-month period (beginning on or
                after the Effective Date) the persons who were directors of
                either the Bank or the Company immediately before the beginning
                of such twelve-month period (the "Incumbent Directors") shall
                cease to constitute at least a majority of such board of
                directors; provided that any director who was not a director as
                of the Effective Date shall be deemed to be an Incumbent
                Director if that director was elected to such board of directors
                by, or on the recommendation of or with the approval of, at
                least two-thirds (2/3) of the directors who then qualified as
                Incumbent Directors; and provided further that no director whose
                initial assumption of office is in connection with an actual or
                threatened election contest (relating to the election of
                directors) shall be deemed to be an Incumbent Director;

                        (c)     the approval by the stockholders of either the
                Bank or the Company of a reorganization, merger or
                consolidation, with respect to which persons who were the
                stockholders of the Bank or the Company, as the case may be,
                immediately prior to such reorganization, merger or
                consolidation do not, immediately thereafter, own more than
                fifty percent (50%) of the combined voting power entitled to
                vote in the election of directors of the reorganized, merged or
                consolidated company's then outstanding voting securities; or

                        (d)     the sale, transfer or assignment of all or
                substantially all of the assets of the Company and its
                subsidiaries to any third party.

        1.7     "CONFIDENTIAL INFORMATION" means data and information relating
to the business of the Employer (which does not rise to the status of a Trade
Secret) which is or has been disclosed to the Employee or of which the Employee
became aware as a consequence of or through the Employee's relationship to the
Employer and which has value to the Employer and is not generally known to its
competitors. Confidential Information shall not include any data or information
that has been voluntarily disclosed to the public by the Employer (except where
such public disclosure has been made by the Employee without authorization) or
that has been independently developed and disclosed by others, or that otherwise
enters the public domain through lawful means.

        1.8     "EFFECTIVE DATE" shall mean April 26, 2004.

        1.9     "EMPLOYER INFORMATION" means Confidential Information and Trade
Secrets.

                                      -3-
<PAGE>

        1.10    "INITIAL TERM" shall mean that period of time commencing on the
Effective Date and running until the earlier of the close of business on the
last business day immediately preceding the first anniversary of the Effective
Date or any termination of employment of the Employee under this Agreement as
provided for in Section 3.

        1.11    "PERMANENT DISABILITY" shall mean the total inability of the
Employee to perform his duties under this Agreement for the duration of the
short-term disability period under the Employer's policy then in effect as
certified by a physician chosen by the Employer and reasonably acceptable to the
Employee.

        1.12    "TERM" shall mean the Initial Term and all subsequent renewal
periods.

        1.13    "TRADE SECRETS" means Employer information including, but not
limited to, technical or nontechnical data, formulas, patterns, compilations,
programs, devices, methods, techniques, drawings, processes, financial data,
financial plans, product plans or lists of actual or potential customers or
suppliers which (a) derives economic value, actual or potential, from not being
generally known to, and not being readily ascertainable by proper means by,
other persons who can obtain economic value from its disclosure or use; and (b)
is the subject of efforts that are reasonable under the circumstances to
maintain its secrecy.

2.      DUTIES.

        2.1     POSITION. The Employee is employed as the President of the Bank
and the Company and, subject to the direction of the Board of Directors of the
Bank or of the Company, as applicable, or their designee(s), shall perform and
discharge well and faithfully the duties which may be assigned to him from time
to time by the Bank or the Company in connection with the conduct of its
business. The duties and responsibilities of the Employee are set forth on
EXHIBIT A attached hereto.

        2.2     FULL-TIME STATUS. In addition to the duties and responsibilities
specifically assigned to the Employee pursuant to Section 2.1 hereof, the
Employee shall: (a) devote substantially all of his time, energy and skill
during regular business hours to the performance of the duties of his employment
(reasonable vacations and reasonable absences due to illness excepted) and
faithfully and industriously perform such duties; (b) diligently follow and
implement all management policies and decisions communicated to him by the Board
of Directors of either the Bank or the Company; and (c) timely prepare and
forward to the Board of Directors of either the Bank or the Company all reports
and accounting as may be requested of the Employee.

        2.3     PERMITTED ACTIVITIES. The Employee shall devote his entire
business time, attention and energies to the Business of the Employer and shall
not during the Term be engaged (whether or not during normal business hours) in
any other business or professional activity, whether or not such activity is
pursued for gain, profit or other pecuniary advantage; but this shall not be
construed as preventing the Employee from (a) investing his personal assets in
businesses which (subject to clause (b) below) are not in competition with the
Business of the Employer and which will not require any services on the part of
the Employee in their operation or affairs and in which his participation is
solely that of an investor, (b) purchasing securities in any corporation

                                      -4-
<PAGE>

whose securities are regularly traded provided that such purchase shall not
result in him collectively owning beneficially at any time five percent (5%) or
more of the equity securities of any business in competition with the Business
of the Employer; and (c) participating in civic and professional affairs and
organizations and conferences, preparing or publishing papers or books or
teaching so long as the Board of Directors of either the Bank or the Company
approves of such activities prior to the Employee's engaging in them.

3.      TERM AND TERMINATION.

        3.1     TERM. This Agreement shall remain in effect for the Term.
Commencing with the first day of the Initial Term, the Term shall renew each day
such that the Term remains a one-year term from day-to-day thereafter unless
either party gives written notice to the other of its or his intent that the
automatic renewals shall cease. In the event such notice of non-renewal is
properly given, this Agreement and the Term shall expire on the first
anniversary of the thirtieth (30th) day following the date such written notice
is received.

        3.2     TERMINATION. During the Term, the employment of the Employee
under this Agreement may be terminated only as follows:

                3.2.1   By the Employer:

                        (a)     For Cause, upon written notice to the Employee
                pursuant to Section 1.5.1 hereof, in which event the Employer
                shall have no further obligation to the Employee except for the
                payment of any amounts earned and unpaid under Section 4 on the
                effective date of termination;

                        (b)     Without Cause at any time, provided that the
                Employer shall give the Employee thirty (30) days' prior written
                notice of its intent to terminate, in which event the Employer
                shall be required to continue to meet its obligations to the
                Employee under Sections 4.1 and 4.2 for a period equal to twelve
                (12) months following the effective date of termination and
                under Section 4.4 to the extent provided in that Section; or

                        (c)     Upon the Permanent Disability of Employee at any
                time, provided that the Employer shall give the Employee thirty
                (30) days' prior written notice of its intent to terminate, in
                which event the Employer shall be required to continue to meet
                its obligations to the Employee under Sections 4.1 and 4.2 for a
                period of twelve (12) months following the effective date of
                termination, and under Section 4.4 to the extent provided in
                that Section.

                3.2.2   By the Employee:

                        (a)     For Cause, provided that the Employee shall give
                the Employer sixty (60) days' prior written notice of his intent
                to terminate, in which event the Employer shall be required to
                continue to meet its obligations to the Employee under Sections
                4.1 and 4.2 for a period equal to twelve (12) months following
                the

                                      -5-
<PAGE>

                effective date of termination and under Section 4.4 to the
                extent provided in that Section;

                        (b)     Without Cause, provided that the Employee shall
                give the Employer sixty (60) days' prior written notice of his
                intent to terminate, in which event the Employer shall have no
                further obligation to the Employee except payment of any amounts
                earned and unpaid under Section 4 on the effective date of the
                termination; or

                        (c)     Upon the Permanent Disability of the Employee,
                in which event the Employer shall be required to continue to
                meet its obligation to the Employee under Sections 4.1 and 4.2
                for six (6) months following the effective date of termination.

        3.3     If, within twelve (12) months prior to or twenty-four (24)
months following a Change in Control, the Employee terminates his employment for
Cause or the Employer terminates the Employee's employment without Cause, the
Employer shall be required to pay the Employee in cash a lump sum payment in an
amount equal to 2.99 multiplied by the sum of (a) the average of the Employee's
Base Salary paid over the immediately preceding three (3) calendar years or, if
less, over the Employee's entire employment history with the Employer and (b)
the average of the annual Incentive Compensation (as defined below) paid over
the immediately preceding three (3) calendar years or, if less, over the
Employee's entire employment history with the Employer, which amount shall be
paid to the Employee no later than ninety (90) days following the effective date
of termination. Notwithstanding any other provision in this Agreement, if the
aggregate present value (determined as of the date of the Change in Control in
accordance with the provisions of Code Section 280G) of the payment payable
under this Agreement would be subject to the excise tax imposed by Code Section
4999 or any successor thereto, the Employer shall pay the Employee such
additional compensation as is necessary (a "Gross-Up Payment"), after taking
into account all federal, state and local income taxes payable by the Employee
as a result of the receipt of such additional compensation, to place the
Employee in the same after-tax position (including federal, state and local
taxes) he would have been in had no excise tax or any related interest or
penalties been payable by the Employee. The Board of Directors of the Employer
shall make a reasonable determination as to whether and when a Gross-Up Payment
is required and the amount of such Gross-Up Payment.

        3.4     TERMINATION BY AGREEMENT. At any time upon mutual, written
agreement of the parties, in which event the Employer shall have no further
obligation to the Employee except for the payment of any amounts earned and
unpaid under Section 4 on the effective date of termination.

        3.5     TERMINATION UPON DEATH. Notwithstanding anything in this
Agreement to the contrary, the Term shall end automatically upon the Employee's
death, in which event the Employer shall have no further obligation to the
Employee except for the payment of any amounts earned and unpaid under Section 4
on the effective date of termination.

        3.6     EFFECT OF TERMINATION. Termination of the employment of the
Employee pursuant to Section 3 shall be without prejudice to any right or claim
which may have previously accrued to

                                      -6-
<PAGE>

either the Employer or the Employee hereunder and shall not terminate, alter,
supersede or otherwise affect the terms and covenants and the rights and duties
prescribed in this Agreement. Upon termination of the Employee's employment, the
Employer shall have no further obligation to the Employee or the Employee's
estate, except for payment of any amounts earned and unpaid under Section 4 on
the effective date of termination and any payments set forth in Sections
3.2.1(b) or (c), Section 3.2.2(a) or (c); Section 3.3 or Section 3.5, as
applicable.

4.      COMPENSATION. The Employee shall receive the following salary and
benefits:

        4.1     BASE SALARY. The Employee shall be compensated at a base rate of
$192,000 annually (the "Base Salary"). The Employee's Base Salary shall be
reviewed by the Boards of Directors of the Bank and the Company annually, and
the Employee shall be entitled to receive annually an increase in such amount,
if any, as may be determined by such Boards of Directors collectively. Base
Salary shall be payable in accordance with the Employer's normal payroll
practices.

        4.2     INCENTIVE COMPENSATION. The Employee shall be entitled to annual
bonus compensation, if any, in accordance with the terms specified in EXHIBIT B
attached hereto.

        4.3     STOCK OPTIONS. The Employee shall be eligible to receive stock
options as determined in the discretion of the Board of Directors of the
Company.

                (a)     As of the closing date of the Company's public offering
        of its common stock described in the Form S-2 Registration Statement
        filed with the Securities Exchange Commission on June 3, 2004 (the
        "Offering"), the Employer will grant to the Employee an incentive stock
        option to purchase, at a per share purchase price equal to the fair
        market value of the Company's common stock on the grant date, a number
        of shares of the Company's common stock which is equal to five percent
        (5%) of the number of shares of the Company's common stock which are
        sold in the Offering. The option will become vested and exercisable in
        20% increments, commencing on the first anniversary of the closing date
        of the Offering and continuing for the next four successive
        anniversaries until the option is fully vested and exercisable. The
        option shall expire generally upon the earlier of ninety (90) days
        following termination of employment or upon the tenth anniversary of the
        option grant date.

                (b)     In the event of a Change in Control or upon the death or
        Permanent Disability of the Employee during the Term, the options
        granted pursuant to this Agreement shall become one hundred percent
        (100%) vested and exercisable.

        4.4     HEALTH INSURANCE.

                (a)     The Employee shall be entitled to participate in the
        health insurance plan provided by the Employer for its employees. The
        Employer will pay the full cost of the premiums under such plan for
        health insurance coverage for the Employee.

                                      -7-
<PAGE>

                (b)     In the event of (i) termination by the Employee for
        Cause (Section 3.2.2(a)), or (ii) termination by the Employee following
        a Change in Control (Section 3.3), the Employer shall reimburse Employee
        for the cost of premium payments paid by the Employee to continue his
        then existing health insurance as provided by the Employer for a period
        of six (6) months following the date of termination of employment.

                (c)     In the event of termination by the Employer without
        Cause (Section 3.2.1(b)) or upon the Disability of the Employee (Section
        3.2.1(c)), the Employer shall reimburse the Employee for the cost of
        premium payments paid by the Employer to continue his then existing
        health insurance as provided by the Employer for a period of twelve (12)
        months following the date of termination of employment.

        4.5     AUTOMOBILE. Beginning as of the Effective Date, the Employer
will provide Employee with an automobile to be used by the Employee for business
and personal purposes. The make and model of the automobile shall be determined
by the Employer. The Employer will pay expenses associated with the operation,
maintenance, repair and insurance for the automobile.

        4.6     BUSINESS EXPENSES; MEMBERSHIPS. The Employer specifically agrees
to reimburse the Employee for (a) reasonable business (including travel)
expenses incurred by him in the performance of his duties hereunder, as approved
from time to time by the Board of Directors of either the Bank or the Company,
and (b) the dues and business related expenditures, including initiation fees,
associated with membership in two country clubs and two civic associations both
as selected by the Employee and in professional associations which are
commensurate with his position; provided, however, that the Employee shall, as a
condition of reimbursement, submit verification of the nature and amount of such
expenses in accordance with reimbursement policies from time to time adopted by
the Employer and in sufficient detail to comply with rules and regulations
promulgated by the Internal Revenue Service.

        4.7     VACATION. On a non-cumulative basis the Employee shall be
entitled to four (4) weeks of vacation in each successive twelve-month period
during the Term, during which his compensation shall be paid in full. The
Employee will endeavor to take at least two (2) consecutive weeks each year for
vacation, with other vacation to be taken at the time the Employer determines
appropriate, taking into account the requirements of the Employer.

        4.8     LIFE INSURANCE. During the Term, the Employer will provide the
Employee with term life insurance coverage providing a death benefit of not less
than $500,000, payable to such beneficiary or beneficiaries as the Employee may
designate.

        4.9     BENEFITS. In addition to the benefits specifically described
herein, the Employee shall be entitled to such benefits as may be available from
time to time for executives of the Employer similarly situated to the Employee.
All such benefits shall be awarded and administered in accordance with the
Employer's standard policies and practices. Such benefits may include, by way of
example only, profit-sharing plans, retirement or investment funds, dental,
health, life and disability insurance benefits and such other benefits as the
Employer deems appropriate. The Employer makes no representation to the Employee
regarding the taxability or nontaxability of any benefits provided under Section
4.

                                      -8-
<PAGE>

        4.10    WITHHOLDING. The Employer may deduct from each payment of
compensation hereunder all amounts required to be deducted and withheld in
accordance with applicable federal and state income, FICA and other withholding
requirements.

5.      EMPLOYER INFORMATION.

        5.1     OWNERSHIP OF INFORMATION. All Employer Information received or
developed by the Employee while employed by the Employer will remain the sole
and exclusive property of the Employer.

        5.2     OBLIGATIONS OF THE EMPLOYEE. The Employee agrees (a) to hold
Employer Information in strictest confidence, and (b) not to use, duplicate,
reproduce, distribute, disclose or otherwise disseminate Employer Information or
any physical embodiments thereof and may in no event take any action causing or
fail to take any action necessary in order to prevent any Employer Information
from losing its character or ceasing to qualify as Confidential Information or a
Trade Secret. In the event that the Employee is required by law to disclose any
Employer Information, the Employee will not make such disclosure unless (and
then only to the extent that) the Employee has been advised by independent legal
counsel that such disclosure is required by law and then only after prior
written notice is given to the Company when the Employee becomes aware that such
disclosure has been requested and is required by law. This Section 5 shall
survive for a period of six (6) months following termination of this Agreement
for any reason with respect to Confidential Information, and shall survive
termination of this Agreement for any reason for so long as is permitted by the
then-current Georgia Trade Secrets Act of 1990, O.C.G.A. ss.ss.
10-1-760-10-1-767, with respect to Trade Secrets.

        5.3     DELIVERY UPON REQUEST OR TERMINATION. Upon request by the
Employer, and in any event upon termination of his employment with the Employer,
the Employee will promptly deliver to the Employer all property belonging to the
Employer, including, without limitation, all Employer Information then in his
possession or control.

6.      NON-COMPETITION. The Employee agrees that during his employment by the
Employer hereunder and, in the event of his termination by the Employer for
Cause pursuant to Section 3.2.1(a), by the Employee without Cause pursuant to
Section 3.2.2(b) or by the Employee in connection with a Change in Control
pursuant to Section 3.3, for a period of twelve (12) months thereafter, he will
not (except on behalf of or with the prior written consent of the Employer),
within the Area, either directly or indirectly, on his own behalf or in the
service or on behalf of others, as a principal, partner, officer, director,
manager, supervisor, administrator, consultant, executive employee or in any
other capacity which involves duties and responsibilities similar to those
undertaken for the Employer, or engage in any business which is the same as or
essentially the same as the Business of the Employer.

7.      NON-SOLICITATION OF CUSTOMERS. The Employee agrees that during his
employment by the Employer hereunder and, in the event of his termination by the
Employer for Cause pursuant to Section 3.2.1(a), by the Employee without Cause
pursuant to Section 3.2.2(b) or by the Employee in connection with a Change in
Control pursuant to Section 3.3, for a period of twelve (12) months

                                      -9-
<PAGE>

thereafter, he will not (except on behalf of or with the prior written consent
of the Employer), within the Area, on his own behalf or in the service or on
behalf of others, solicit, divert or appropriate or attempt to solicit, divert
or appropriate, directly or by assisting others, any business from any of the
Employer's customers, including actively sought prospective customers, with whom
the Employee has or had material contact during the last two (2) years of his
employment, for purposes of providing products or services that are competitive
with those provided by the Employer.

8.      NON-SOLICITATION OF EMPLOYEES. The Employee agrees that during his
employment by the Employer hereunder and, in the event of his termination by the
Employer for Cause pursuant to Section 3.2.1(a), by the Employee without Cause
pursuant to Section 3.2.2(b) or by the Employee in connection with a Change in
Control pursuant to Section 3.3, for a period of twelve (12) months thereafter,
he will not, within the Area, on his own behalf or in the service or on behalf
of others, solicit, recruit or hire away or attempt to solicit, recruit or hire
away, directly or by assisting others, any employee of the Employer or its
Affiliates, whether or not such employee is a full-time employee or a temporary
employee of the Employer or its Affiliates and whether or not such employment is
pursuant to a written agreement and whether or not such employment is for a
determined period or is at will.

9.      REMEDIES. The Employee agrees that the covenants contained in Sections 5
through 8 of this Agreement are of the essence of this Agreement; that each of
the covenants is reasonable and necessary to protect the business, interests and
properties of the Employer; and that irreparable loss and damage will be
suffered by the Employer should he breach any of the covenants. Therefore, the
Employee agrees and consents that, in addition to all the remedies provided by
law or in equity, the Employer shall be entitled to a temporary restraining
order and temporary and permanent injunctions to prevent a breach or
contemplated breach of any of the covenants. The Employer and the Employee agree
that all remedies available to the Employer or the Employee, as applicable,
shall be cumulative.

10.     SEVERABILITY. The parties agree that each of the provisions included in
this Agreement is separate, distinct and severable from the other provisions of
this Agreement and that the invalidity or unenforceability of any Agreement
provision shall not affect the validity or enforceability of any other provision
of this Agreement. Further, if any provision of this Agreement is ruled invalid
or unenforceable by a court of competent jurisdiction because of a conflict
between the provision and any applicable law or public policy, the provision
shall be redrawn to make the provision consistent with and valid and enforceable
under the law or public policy.

11.     NO SET-OFF BY THE EMPLOYEE. The existence of any claim, demand, action
or cause of action by the Employee against the Employer, or any Affiliate of the
Employer, whether predicated upon this Agreement or otherwise, shall not
constitute a defense to the enforcement by the Employer of any of its rights
hereunder.

12.     NOTICE. All notices and other communications required or permitted under
this Agreement shall be in writing and, if mailed by prepaid first-class mail or
certified mail, return receipt requested, shall be deemed to have been received
on the earlier of the date shown on the receipt or three (3) business days after
the postmarked date thereof. In addition, notices hereunder may be

                                      -10-
<PAGE>

delivered by hand, facsimile transmission or overnight courier, in which event
the notice shall be deemed effective when delivered or transmitted. All notices
and other communications under this Agreement shall be given to the parties
hereto at the following addresses:

                (i)     If to the Employer, to it at:

                        2815 Meredyth Drive
                        Albany, GA  31707

                (ii)    If to the Employee, to him at:

                        Robert E. Lee
                        5101 Old Dawson Road
                        Albany, Georgia  31707

13.     ASSIGNMENT. Neither party hereto may assign or delegate this Agreement
or any of its rights and obligations hereunder without the written consent of
the other party hereto.

14.     WAIVER. A waiver by the Employer of any breach of this Agreement by the
Employee shall not be effective unless in writing, and no waiver shall operate
or be construed as a waiver of the same or another breach on a subsequent
occasion.

15.     ARBITRATION. Any controversy or claim arising out of or relating to this
contract, or the breach thereof, shall be settled by binding arbitration in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association. Judgment upon the award rendered by the arbitrator may be entered
only in the State Court of Dougherty County or the federal court for the Middle
District of Georgia. The Employer and the Employee agree to share equally the
fees and expenses associated with the arbitration proceedings.

16.     ATTORNEYS' FEES. In the event that the parties have complied with this
Agreement with respect to arbitration of disputes and litigation ensues between
the parties concerning the enforcement of an arbitration award, the Employer
shall pay all costs and expenses in connection with such litigation until such
time as a final determination (excluding any appeals) is made with respect to
the litigation. If the Employer prevails on the substantive merits of each
material claim in dispute in such litigation, the Employer shall be entitled to
receive from the Employee all reasonable costs and expenses, including without
limitation attorneys' fees, incurred by the Employer on behalf of the Employee
in connection with such litigation, and the Employee shall pay such costs and
expenses to the Employer promptly upon demand by the Employer.

17.     APPLICABLE LAW. This Agreement shall be construed and enforced under and
in accordance with the laws of the State of Georgia.

18.     INTERPRETATION. Words importing any gender include all genders. Words
importing the singular form shall include the plural and vice versa. The terms
"herein", "hereunder", "hereby", "hereto", "hereof" and any similar terms refer
to this Agreement. Any captions, titles or headings preceding the text of any
article, section or subsection herein are solely for convenience of

                                      -11-
<PAGE>

reference and shall not constitute part of this Agreement or affect its meaning,
construction or effect.

19.     ENTIRE AGREEMENT. This Agreement embodies the entire and final agreement
of the parties on the subject matter stated in the Agreement. No amendment or
modification of this Agreement shall be valid or binding upon the Employer or
the Employee unless made in writing and signed by both parties. All prior
understandings and agreements relating to the subject matter of this Agreement
are hereby expressly terminated.

20.     RIGHTS OF THIRD PARTIES. Nothing herein expressed is intended to or
shall be construed to confer upon or give to any person, firm or other entity,
other than the parties hereto and their permitted assigns, any rights or
remedies under or by reason of this Agreement.

21.     SURVIVAL. The obligations of the Employee pursuant to Sections 5, 6, 7,
8 and 9 shall survive the termination of the employment of the Employee
hereunder for the period designated under each of those respective sections.

22.     JOINT AND SEVERAL. The obligations of the Bank and the Company to the
Employee hereunder shall be joint and several.

                  [Remainder of Page Intentionally Left Blank]

                                      -12-
<PAGE>

        IN WITNESS WHEREOF, the Employer and the Employee have executed and
delivered this Agreement as of the date first shown above.

                                      THE BANK:

                                      ALBANY BANK & TRUST,
                                      NATIONAL ASSOCIATION

                                      By:           /s/ Charles M. Jones, III
                                               ---------------------------------
                                      Print Name:   Charles M. Jones, III
                                                   -----------------------------
                                      Title:        Chief Executive Officer
                                              ----------------------------------

                                      THE COMPANY:

                                      COMMUNITY CAPITAL BANCSHARES, INC.

                                      By:           /s/ Charles M. Jones, III
                                               ---------------------------------
                                      Print Name:   Charles M. Jones, III
                                                   -----------------------------
                                      Title:        Chief Executive Officer
                                              ----------------------------------

                                      THE EMPLOYEE:

                                      /s/ Robert E. Lee
                                      ------------------------------------------
                                      ROBERT E. LEE

                                      -13-
<PAGE>

                                    Exhibit A
                                    ---------

                             Duties of the Employee

The duties of the Employee shall include, in addition to any other duties
assigned the Employee by the Board of Directors of the Bank or the Company or
their respective designees, the following:

        o       Foster a corporate culture that promotes ethical practices,
        encourages individual integrity, fulfills social responsibility, and is
        conducive to attracting, retaining and motivating a diverse group of
        top-quality employees at all levels.

        o       Work with the Board of Directors to develop a long-term strategy
        for the Company that creates shareholder value.

        o       Develop and recommend to the Board annual business plans and
        budgets that support the Company's long-term strategy.

        o       Manage the day-to-day business affairs of the Company
        appropriately.

        o       Use best efforts to achieve the Company's financial and
        operating goals and objectives.

        o       Improve the quality and value of the products and services
        provided by the Company.

        o       Ensure that the Company maintains a satisfactory competitive
        position within its industry.

        o       Develop an effective management team and an active plan for its
        development and succession, and make recommendations to the Board
        regarding hiring, firing and compensation.

        o       Implement major corporate policies. [NOTE: REVISE DUTIES AS
        NECESSARY]

<PAGE>

                                    Exhibit B
                                    ---------

Within ninety (90) days following the end of each calendar year of the
Employer's operations, the Employer shall pay the Employee a cash bonus equal to
the greater of (1) five percent (5%) of the Employer's consolidated pre-tax
earnings for that calendar year or (2) if the Employer meets or exceeds its
consolidated budgeted performance goals for the calendar year, $15,000 plus ten
percent (10%) of the positive difference between the Employer's consolidated
actual performance and budgeted performance with regard to pre-tax earnings (or
loss); provided, however, if the Employer does not meet its consolidated
budgeted performance goals for the calendar year, then this clause (2) shall be
deemed to be $0.00 (the "Incentive Compensation"). Notwithstanding the
foregoing, the Incentive Compensation payments contemplated by this Exhibit B
shall not become due and payable until the Board of Directors of the Bank has
determined, according to reasonable safety and soundness standards, that the
overall financial condition of the Bank, including asset quality, will not be
adversely affected by the payment of said amounts.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]